Home/Pipeline/ALETA-002

ALETA-002

Solid Tumors

DiscoveryActive

Key Facts

Indication

Solid Tumors

Phase

Discovery

Status

Active

Company

Aleta Biotherapeutics

About Aleta Biotherapeutics

Aleta Biotherapeutics is pioneering a novel approach to overcome limitations of CAR T-cell therapies, particularly antigen escape and relapse. Its proprietary CAR T Engager (CTE) proteins are off-the-shelf biologics that bind to cancer cells and 're-target' them for destruction by a patient's existing CAR T cells, effectively boosting antigen density and preventing resistance. With its lead asset, ALETA-001, in a Phase I/II trial supported by Cancer Research UK and holding key regulatory designations, the company is initially targeting the significant unmet need in lymphoma and myeloma, with a preclinical pipeline extending into AML and solid tumors. Aleta is a private company leveraging a capital-efficient, asset-centric model to advance its platform.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed